TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study

BACKGROUND: Currently, no specific treatment exists for heart failure with preserved ejection fraction (HFpEF). Left ventricular (LV) relaxation during diastole is a highly energy-demanding process, while energy homeostasis is known to be compromised in HFpEF. We hypothesise that trimetazidine – a f...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Bovenkamp, A. A., Bakermans, A. J., Allaart, C. P., Nederveen, A. J., Kok, W. E. M., van Rossum, A. C., Handoko, M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2020
Materias:
Original Article – Study Design Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270414/
https://www.ncbi.nlm.nih.gov/pubmed/32162204
http://dx.doi.org/10.1007/s12471-020-01407-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270414/
https://www.ncbi.nlm.nih.gov/pubmed/32162204
http://dx.doi.org/10.1007/s12471-020-01407-z

Ejemplares similares